A Phase 3 biopharmaceutical company, (stellar-genelux.com) Issuser Address: GA4WCR7NLD4OJBAJODY75NVA65OITN2EGDZNPDQ6TXL3XLKA4BUVSYDX ICO On 10/12/2023 CB:40,000%
Genelux operates from several locations in Southern California, with their headquarters and business offices in the ?Los Angeles region and their R&D and manufacturing facilities in San Diego, a notable biotech hub in the ??United States.?
⚡️Their strategy involves leveraging internal capabilities in the clinical development of ?oncolytic virotherapies to become a ?leading immunotherapy company. This includes advancing Olvi-Vec through ?clinical development and seeking regulatory approval, supporting various ?partners and ?licensees in the development of Olvi-Vec and other products, and utilizing their CHOICE™ discovery ?platform to develop a portfolio of oncology product candidates.?
?They also aim to broaden their manufacturing capabilities and transform into a ?fully integrated therapeutics company.
Genelux Corporation is a Phase 3 biopharmaceutical company. Their products, especially Olvi-Vec, have ?advanced to late-stage clinical trials, demonstrating their ⚡️commitment to rigorous scientific research and their ?progress towards regulatory approval.?
?Genelux presents a ?valuable investment in the growing field of ?biopharmaceuticals. Their focus on ?developing treatments for difficult-to-treat cancers fills a significant gap in the ?market, offering substantial growth potential.?
▶️An investment in Genelux Corporation is not just a financial venture; it is a commitment to transforming the future of cancer treatment. Together, we can make a significant impact on the lives of those suffering from these devastating diseases.
| Health Care |
Pharmaceutical |